N/A N=2,029 Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)
Non-small Cell Lung Cancer
Primary: Number of Participants With Adverse Drug Reactions — 1858; 518 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=55 Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China
Rheumatoid Arthritis
Primary: Median Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score at Week 24 — -0.3 units on a scale — p==0.0002
Early Phase 1 N=15 Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation
Rosacea
Primary: Kallikrein 5 (KLK5) Protease Activity — 581.1; 816.5 RFU/uL
Phase 2 N=26 The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
Stroke · Cerebrovascular Accident (CVA) · Hemiparesis
Primary: Mean Percent Change From Baseline in Area Under the Curve for Objectively Measured Spastic Catch Response of the Wrist Flexors at Fast Speed — 13.678; -8.783; 15.927…
N/A N=38 NCCL Direct Composite Restoration Performance With Self-Etch and Multimode Adhesives
Dental Adhesives/Restorations Performance
Primary: Esthetic, Functional and Biological Clinical Performance Adhesive/Adhesion Mode of NCCLs Restoration, Graded on a 5-point Scale, Using FDI Criteria at 24 Month Follow-up…
N/A N=60 LLLT for Reducing Waste Circumference and Weight
Weight Loss
Primary: Change in Weight — -0.5; -0.9; -0.6 Kg — p=0.723
Phase 1 N=31 Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
Solid Tumours
Primary: Maximum Plasma Concentration (Cmax) — 7.32; 8.25; 6.40 μg/mL
N/A N=171 Shear Wave Sonoelastography in Pediatric Liver Fibrosis
Sonoelastography · Elastography · Elastograms
Primary: 2D-SWE Measurements' Capability of Predicting Stages of Fibrosis Based on METAVIR Scoring System — NA; 96.9; 95.2; 1.00 percentage of exams
Phase 4 N=118 NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
Mild to Moderate Alzheimer's Disease
Primary: MMSE Total Score: Change From Baseline to Week 8 and Week 24 (Full Analysis Set) — 17.33; 0.29; -0.36 scores on a scale — p=0.1750
Phase 2 N=16 Ambrisentan in Single Ventricle
Hypoplastic Left Heart Syndrome · Hypoplastic Right-sided Heart Complex
Primary: Area Under the Curve for Ambrisentan Plasma Concentration — 7871.46 ng*hr/mL
Phase 2 N=12 Phase II Study of Perindopril and Regorafenib in mCRC
Metastatic Colorectal Cancer
Primary: Number of Participants That Have Any Grade HFSR Toxicity — 7 Participants
Phase 2 N=78 Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
Ovarian Cancer
Primary: Number of Participants With Overall Response — 1; 3 Participants
Phase 1 N=13 A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation
Smoking Cessation
Primary: Maximum Concentration (Cmax) — 26.2; 32.9 ng/mL
N/A N=23 Effects of Reducing Indoor Air Pollution on the Adult Asthmatic Response
Asthma
Primary: PM2.5 Concentration (ug/m^3) — 18.95; 32.73 ug/m^3
Phase 3 N=802 Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma
Mild Asthma
Primary: Trough FEV1 — 2.562; 2.379 Liters — p=<0.001